| Year |
Citation |
Score |
| 2024 |
Khatiwada P, Rimal U, Han Z, Shemshedini L. MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer. Endocrine Oncology (Bristol, England). 4: e230017. PMID 38410785 DOI: 10.1530/EO-23-0017 |
0.573 |
|
| 2023 |
Khatiwada P, Rimal U, Malla M, Han Z, Shemshedini L. Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation. Endocrine Oncology (Bristol, England). 3: e230010. PMID 37822366 DOI: 10.1530/EO-23-0010 |
0.575 |
|
| 2023 |
Khatiwada P, Rimal U, Han Z, Malla M, Zhou J, Shemshedini L. The Transmembrane Protein TM4SF3 Interacts With AR and AR-V7 and is Recruited to AR Target Genes. Endocrinology. 164. PMID 36951301 DOI: 10.1210/endocr/bqad048 |
0.531 |
|
| 2022 |
Han Z, Rimal U, Khatiwada P, Brandman J, Zhou J, Hussain M, Viola RE, Shemshedini L. Dual Acting Peptides Target EZH2 and AR: a New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer. Endocrinology. PMID 36288553 DOI: 10.1210/endocr/bqac180 |
0.495 |
|
| 2020 |
Khatiwada P, Kannan A, Malla M, Dreier M, Shemshedini L. Androgen up-regulation of Twist1 gene expression is mediated by ETV1. Peerj. 8: e8921. PMID 32296610 DOI: 10.7717/Peerj.8921 |
0.697 |
|
| 2020 |
Khatiwada P, Malla M, Shemshedini L. Abstract 2072: TM4SF3 interaction with AR or AR-V7 is important for the survival of prostate cancer cells Epidemiology. DOI: 10.1158/1538-7445.Am2020-2072 |
0.608 |
|
| 2017 |
Zhou J, Gao S, Hsieh CL, Malla M, Shemshedini L. Peptide B targets soluble guanylyl cyclase α1 and kills prostate cancer cells. Plos One. 12: e0184088. PMID 28859127 DOI: 10.1371/Journal.Pone.0184088 |
0.675 |
|
| 2017 |
Dayal S, Zhou J, Manivannan P, Siddiqui MA, Ahmad OF, Clark M, Awadia S, Garcia-Mata R, Shemshedini L, Malathi K. RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells. International Journal of Molecular Sciences. 18. PMID 28257035 DOI: 10.3390/Ijms18030529 |
0.594 |
|
| 2015 |
Bhansali M, Zhou J, Shemshedini L. TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins. Molecular Endocrinology (Baltimore, Md.). me20151075. PMID 26649804 DOI: 10.1210/Me.2015-1075 |
0.657 |
|
| 2014 |
Bhansali M, Shemshedini L. COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells. Molecular Endocrinology (Baltimore, Md.). 28: 834-45. PMID 24725084 DOI: 10.1210/Me.2014-1017 |
0.638 |
|
| 2013 |
Gao S, Hsieh CL, Zhou J, Shemshedini L. Zinc Finger 280B regulates sGCα1 and p53 in prostate cancer cells. Plos One. 8: e78766. PMID 24236047 DOI: 10.1371/Journal.Pone.0078766 |
0.741 |
|
| 2013 |
Gao S, Hsieh CL, Bhansali M, Kannan A, Shemshedini L. A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer. Plos One. 8: e64189. PMID 23724033 DOI: 10.1371/Journal.Pone.0064189 |
0.765 |
|
| 2012 |
Cai C, Hsieh CL, Gao S, Kannan A, Bhansali M, Govardhan K, Dutta R, Shemshedini L. Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer. Molecular Endocrinology (Baltimore, Md.). 26: 292-307. PMID 22174378 DOI: 10.1210/Me.2010-0394 |
0.825 |
|
| 2010 |
Periyasamy S, Hinds T, Shemshedini L, Shou W, Sanchez ER. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene. 29: 1691-701. PMID 20023700 DOI: 10.1038/Onc.2009.458 |
0.682 |
|
| 2010 |
Zhang J, Gonit M, Salazar MD, Shatnawi A, Shemshedini L, Trumbly R, Ratnam M. C/EBPα redirects androgen receptor signaling through a unique bimodal interaction Oncogene. 29: 723-738. PMID 19901962 DOI: 10.1038/Onc.2009.373 |
0.683 |
|
| 2009 |
Shemshedini L. Use of reporter genes to study promoters of the androgen receptor. Methods in Molecular Biology (Clifton, N.J.). 590: 195-207. PMID 19763505 DOI: 10.1007/978-1-60327-378-7_12 |
0.583 |
|
| 2008 |
Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells. Journal of Molecular Endocrinology. 41: 13-23. PMID 18469090 DOI: 10.1677/Jme-07-0158 |
0.854 |
|
| 2007 |
Cai C, Hsieh CL, Shemshedini L. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Molecular Cancer Research : McR. 5: 725-35. PMID 17634427 DOI: 10.1158/1541-7786.Mcr-06-0430 |
0.821 |
|
| 2007 |
Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Molecular Endocrinology (Baltimore, Md.). 21: 1835-46. PMID 17505060 DOI: 10.1210/Me.2006-0480 |
0.803 |
|
| 2007 |
Cai C, Omwancha J, Hsieh CL, Shemshedini L. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer and Prostatic Diseases. 10: 39-45. PMID 17003774 DOI: 10.1038/sj.pcan.4500912 |
0.802 |
|
| 2007 |
Cai C, Chen SY, Zheng Z, Omwancha J, Lin MF, Balk SP, Shemshedini L. Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation. Oncogene. 26: 1606-15. PMID 16964290 DOI: 10.1038/Sj.Onc.1209956 |
0.813 |
|
| 2006 |
Omwancha J, Zhou XF, Chen SY, Baslan T, Fisher CJ, Zheng Z, Cai C, Shemshedini L. Makorin RING finger protein 1 (MKRN1) has negative and positive effects on RNA polymerase II-dependent transcription. Endocrine. 29: 363-73. PMID 16785614 DOI: 10.1385/Endo:29:2:363 |
0.735 |
|
| 2006 |
Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL, Shemshedini L. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene. 25: 7212-23. PMID 16732317 DOI: 10.1038/sj.onc.1209705 |
0.804 |
|
| 2006 |
Zheng Z, Cai C, Omwancha J, Chen SY, Baslan T, Shemshedini L. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. The Journal of Biological Chemistry. 281: 4002-12. PMID 16361251 DOI: 10.1074/Jbc.M509260200 |
0.814 |
|
| 2004 |
Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. The Journal of Biological Chemistry. 279: 19191-200. PMID 14985354 DOI: 10.1074/Jbc.M309560200 |
0.639 |
|
| 2001 |
Bubulya A, Chen SY, Fisher CJ, Zheng Z, Shen XQ, Shemshedini L. c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor. The Journal of Biological Chemistry. 276: 44704-11. PMID 11577103 DOI: 10.1074/Jbc.M107346200 |
0.662 |
|
| 2001 |
Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. The Journal of Biological Chemistry. 276: 38472-9. PMID 11504717 DOI: 10.1074/Jbc.M103652200 |
0.801 |
|
| 2000 |
Bubulya A, Zhou XF, Shen XQ, Fisher CJ, Shemshedini L. c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription. Endocrine. 13: 55-62. PMID 11051047 DOI: 10.1385/Endo:13:1:55 |
0.648 |
|
| 1999 |
Shen XQ, Bubulya A, Zhou XF, Khazak V, Golemis EA, Shemshedini L. Ligand-free RAR can interact with the RNA polymerase II subunit hsRPB7 and repress transcription. Endocrine. 10: 281-9. PMID 10484292 DOI: 10.1007/Bf02738627 |
0.575 |
|
| 1999 |
Zhou XF, Shen XQ, Shemshedini L. Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization. Molecular Endocrinology (Baltimore, Md.). 13: 276-85. PMID 9973257 DOI: 10.1210/Mend.13.2.0237 |
0.628 |
|
| 1998 |
Tillman K, Oberfield JL, Shen XQ, Bubulya A, Shemshedini L. c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation Endocrine. 9: 193-200. PMID 9867253 DOI: 10.1385/Endo:9:2:193 |
0.462 |
|
| 1998 |
Wise SC, Burmeister LA, Zhou XF, Bubulya A, Oberfield JL, Birrer MJ, Shemshedini L. Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene. 16: 2001-9. PMID 9591784 DOI: 10.1038/Sj.Onc.1201697 |
0.646 |
|
| 1996 |
Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L. c-Jun can mediate androgen receptor-induced transactivation Journal of Biological Chemistry. 271: 24583-24589. PMID 8798722 DOI: 10.1074/Jbc.271.40.24583 |
0.502 |
|
| 1996 |
Rudert F, Visser E, Gradl G, Grandison P, Shemshedini L, Wang Y, Grierson A, Watson J. pLEF, a novel vector for expression of glutathione S-transferase fusion proteins in mammalian cells Gene. 169: 281-282. PMID 8647462 DOI: 10.1016/0378-1119(95)00820-9 |
0.348 |
|
| 1992 |
Shemshedini L, Ji J, Brou C, Chambon P, Gronemeyer H. In vitro activity of the transcription activation functions of the progesterone receptor: Evidence for intermediary factors Journal of Biological Chemistry. 267: 1834-1839. PMID 1730721 |
0.307 |
|
| 1991 |
Shemshedini L, Knauthe R, Sassone-Corsi P, Pornon A, Gronemeyer H. Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors Embo Journal. 10: 3839-3849. PMID 1935903 |
0.442 |
|
| Show low-probability matches. |